This week The European Society for Medical Oncology (ESMO) is meeting in Geneva Switzerland for its ESMO Immuno-Oncology Congress with immunotherapy basics, latest research results, different treatment options and interpretation of new data on the agenda.
You might also like: ‘The Death of Cancer’ - The Patient Perspective
A highlight of the congress is the 2019 ESMO Award for Immuno-Oncology which is being presented to Prof. Thomas Gajewski for his work on restoring the anti-cancer immune response in patients resistant to immunotherapy.
“Many of us have been doing research in the field of cancer immunotherapy for over 20 years, and it is amazing to see the progress that is currently benefiting so many patients. It is humbling to be recognised as perhaps representative of this group, and especially by my European colleagues,” said Gajewski.
Gajewski is Abbvie Foundation Professor of Cancer Immunotherapy in the Ben May Department for Cancer Research and Professor of Pathology and Medicine at the University of Chicago. He has worked here for more than 20 years on deepening the understanding of anti-tumour immunity for development of new treatment strategies.
The Congress brings together the European community of immuno-oncology stakeholders for the purpose of sharing research, collaboration and networking.
Gajewski is Abbvie Foundation Professor of Cancer Immunotherapy in the Ben May Department for Cancer Research and Professor of Pathology and Medicine at the University of Chicago, where he has worked for more than two decades furthering understanding of fundamental aspects of anti-tumour immunity and translating this into new treatment strategies.
Image credit: University of Chicago Medicine